Boceprevir in genotype 1 chronic hepatitis C: First experiences in Serbia
| Autor: | Kostić, Milotka Fabri, Janković G, Ksenija Bojovic, Babić Js, Zeljko Mijailovic, Petar Svorcan, Jovanović M |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Liver Cirrhosis
medicine.medical_specialty Cirrhosis Genotype Proline Anemia lcsh:Medicine Hepacivirus Antiviral Agents Gastroenterology protease inhibitor chemistry.chemical_compound Pegylated interferon Boceprevir Internal medicine Ribavirin boceprevir medicine Humans chronic hepatitis C Protease Inhibitors Adverse effect business.industry lcsh:R virus diseases General Medicine Hepatitis C Chronic medicine.disease digestive system diseases Surgery Regimen chemistry Tolerability Drug Therapy Combination business Serbia medicine.drug |
| Zdroj: | Srpski Arhiv za Celokupno Lekarstvo, Vol 143, Iss 1-2, Pp 35-41 (2015) |
| ISSN: | 2406-0895 0370-8179 |
| Popis: | Introduction. The triple therapy which consists of one of the protease inhibitor plus pegylated interferon and ribavirin (P/R) is the standard of care for the treatment of chronic hepatitis C virus (HCV) genotype 1(G1) infection both in treatment-na?ve and experienced patients. Objective. The aim of this study was to analyze the efficacy and tolerability of this regime in hospital practice in Serbia. Methods. From July 2012 to October 2012, 20 previously treated patients with advanced fibrosis and HCV G1 infection were included in the triple antiviral regimen in six referral centers in Serbia. All patients were treated with response guide therapy (RGT) regime according to the boceprevir treatment protocol. During the 4-week lead-in period all patients received peginterferon plus ribavirin. After the lead-in period boceprevir was added in the dosage of 800 mg three times a day orally. The subsequent treatment varied according to virologic response and fibrosis. During the therapy HCV RNA level was measured at week 4, 8, 12, 24 of the treatment for the assessment of virologic response profile. All patients who completed therapy were assessed at the end of the treatment and at the end of an additional 24-week treatment-free period for a sustained virologic response (SVR). Results. The total of 20 patients with advanced fibrosis was treated. Among patients with an undetectable HCV RNA level at week 8 the rate of SVR was 100%. No patient with decrease in the HCV RNA level |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|